| 1.67 0.14 (9.15%) | 09-13 15:58 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.95 |
1-year : | 2.27 |
| Resists | First : | 1.66 |
Second : | 1.95 |
| Pivot price | 1.51 |
|||
| Supports | First : | 1.45 |
Second : | 1.33 |
| MAs | MA(5) : | 1.55 |
MA(20) : | 1.47 |
| MA(100) : | 1.5  |
MA(250) : | 1.67 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 84.8 |
D(3) : | 78.1 |
| RSI | RSI(14): 69 |
|||
| 52-week | High : | 2.26 | Low : | 1.28 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ RFL ] has closed above the upper band by 25.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 27.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.67 - 1.68 | 1.68 - 1.69 |
| Low: | 1.53 - 1.54 | 1.54 - 1.55 |
| Close: | 1.66 - 1.67 | 1.67 - 1.68 |
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Thu, 22 Aug 2024
Rafael Holdings Announces Strategic Merger with Cyclo Therapeutics - TipRanks
Thu, 22 Aug 2024
Rafael Holdings and Cyclo Therapeutics To Merge - citybiz
Thu, 22 Aug 2024
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement - StockTitan
Thu, 22 Aug 2024
RFL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Rafael Holdings, Inc. Is Fair to Shareholders - Business Wire
Wed, 22 Nov 2023
Here's Why We're Not Too Worried About Rafael Holdings' (NYSE:RFL) Cash Burn Situation - Yahoo Finance
Thu, 28 Oct 2021
Here's Why Rafael Holdings Is Plummeting Today - The Motley Fool
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Real Estate
|
|
|
Industry:
Real Estate - Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 1.901e+007 (%) |
| Held by Institutions | 21.1 (%) |
| Shares Short | 36 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.022e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -18 % |
| Return on Assets (ttm) | 409.5 % |
| Return on Equity (ttm) | -44.5 % |
| Qtrly Rev. Growth | 540000 % |
| Gross Profit (p.s.) | 358.84 |
| Sales Per Share | -61.07 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0.49 |
| Dividend | 0 |
| Forward Dividend | 38810 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|